

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

John M. L. Ebos,^{1,2} Christina R. Lee,¹ and Robert S. Kerbel^{1,2}

Abstract Despite early benefits seen in cancer patients treated with antivasculature endothelial growth factor (VEGF) pathway-targeted drugs, the clinical benefits obtained in terms of progression-free or overall survival have been more modest than expected. This outcome is, at least in part, due to antiangiogenic drug resistance mechanisms that involve pathways mediated largely by the tumor, whether intrinsic or acquired in response to therapy, or by the host, which is either responding directly to therapy or indirectly to tumoral cues. The focus of this review is to distinguish, where possible, between such host and tumor-mediated pathways of resistance and discuss key challenges facing the pre-clinical and clinical development of antiangiogenic agents, including potential differences in drug efficacies when treating primary tumors or various stages of metastatic disease. (Clin Cancer Res 2009;15(16):5020–5)

Background

The concept of targeting the tumor's vasculature to block its growth has been validated clinically as an anticancer strategy with the approval of three targeted drugs that disrupt the vascular endothelial growth factor (VEGF)-VEGF receptor pathway (1). However, despite encouraging signs from some early preclinical studies that prolonged benefits would be seen in cancer patients, recent findings from the laboratory and clinic have uncovered several limitations to antiangiogenic therapy, posing future challenges for their expanding use. Currently approved antiangiogenic drugs include bevacizumab, the humanized monoclonal antibody to VEGF, as well as small molecule receptor tyrosine kinase inhibitors (RTKIs), such as sorafenib and sunitinib, which target VEGF and platelet-derived growth factor (PDGF) receptors (among a number of others). The VEGF RTKIs (approved thus far as single agents) and bevacizumab (approved for use only in combination with cytotoxic chemotherapy) can lead to disease stabilization and longer periods of progression free survival (PFS) or overall survival (OS) in many patients with metastatic disease, including colorectal carcinoma (CRC), metastatic breast carcinoma (MBC), non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gas-

trointestinal stromal tumors (GIST), and perhaps (though this has yet to be proven) in glioblastoma (GBM; reviewed in ref. 2). But tumors eventually become nonresponsive, or do not respond at all, despite the presence of VEGF and VEGFR-2, and PFS or OS in patients receiving antiangiogenic therapy has translated into benefits measured only in months, in most cases (3). Furthermore, in certain instances, increases in response rate and PFS do not always translate into increased OS for patients, as observed after bevacizumab treatment in RCC (as a single agent; ref. 4) or in MBC (in combination with a taxane chemotherapy; ref. 5). It also remains unclear what role drug combinations play in the efficacy of VEGF pathway targeting (antiangiogenic) inhibitors and why, at least to date, bevacizumab has proved largely ineffective as a single agent whereas VEGF RTKIs, with one recent exception (6), have repeatedly failed in randomized phase III trials when used in combination with chemotherapy (7).

Thus there is a growing interest in understanding the mechanisms of resistance, whether intrinsic or acquired, after exposure to antiangiogenic drug treatment. Early indications are that these mechanisms may be highly diverse, perhaps in part due to the primary mode of action of such drugs, e.g., blocking "host" tumor-supporting processes rather than blocking tumor growth directly. It is possible that resistance to antiangiogenic therapy may extend beyond classical drug resistance seen with traditional cytotoxic chemotherapy and radiation, or even molecular "tumor"-targeted therapy, which include rapid mutability and adaptability inherent to the tumor cells' genetic instability (ref. 8, see review ref. 9). Indeed an emerging question is whether the theoretical advantages of disrupting "host" angiogenic processes may be countered by significant disadvantages, including host-mediated resistance mechanisms involving the vascular microenvironment (perhaps largely independent of the tumor), as well as an altogether more disquieting possibility, namely, that antiangiogenic resistance may, in some instances, eventually increase or induce the invasive and metastatic potential of tumors as a result of therapy.

Authors' Affiliations: ¹Sunnybrook Health Sciences Centre Molecular and Cellular Biology Research and ²Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

Received 6/9/09; accepted 6/11/09; published OnlineFirst 8/11/09.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Requests for reprints: Robert S. Kerbel, Sunnybrook Health Sciences Centre, 2075 Bayview Ave S-217, Toronto, Ontario, M4N 3M5, Canada. Phone: 416-480-5711; Fax: 416-480-5884; E-mail: Robert.Kerbel@sunnybrook.ca.

© 2009 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-09-0095




Fig. 1. Mechanisms of resistance to antiangiogenic therapy may allow for differential efficacy in different stages of disease progression. Tumor-mediated mechanisms, either intrinsic or acquired by primary or established metastatic tumors, allow for evasion of anti-VEGF pathway inhibition. These mechanisms include: (1) tumoral upregulation of compensatory proangiogenic factors; (2) following initial tumor shrinkage, therapy-induced hypoxia mediated adaptation and/or evasion and tumor regrowth via rebound revascularization, vessel co-option, EMT, (3) increased invasiveness; (4) increased intravasive potential. Host-mediated mechanisms, either direct (in response to drug action) or indirect (in response to cues from the tumor), could include (5) BMDC mobilization; (6) microenvironment and/or stromal cell activation; (7) EC dysfunction, inflammation, and/or thrombosis; (8) pericyte dysfunction. Steps 5 through 7 could similarly lead to upregulation of compensatory proangiogenic molecules. Taken together, antiangiogenic therapy may increase tumor extravasative ability (9) and facilitate and/or accelerate disease in microscopic tumors. Legend: EC, endothelial cell; BM, basement membrane; BMDC, bone marrow-derived cell; CAM, compensatory angiogenic molecules; TAFs, tumor-associated fibroblasts; EMT, epithelial-mesenchymal transition.

The focus of this review is to discuss two interrelated pathways. The first includes the proposed main pathways of resistance to antiangiogenic therapy, differentiating between those mediated by either the tumor itself or by the host (or both). The second pathway looks at disease progression from a localized primary tumor to established metastatic disease. It may be critical to consider both pathways simultaneously to understand and overcome some of these challenges facing antiangiogenic therapy, including mechanisms of drug resistance and how they may play a significant role in influencing tumor growth, for better or worse, at various stages of disease (Fig. 1).

Resistance to VEGF Pathway-Targeting Agents

Tumor versus host-mediated pathways. The initial nonresponse seen in a subset of patients receiving VEGF pathway-targeted therapy imply that various tumor cells possess certain *intrinsic* properties that could allow for immediate resistance

upon treatment initiation. These properties could be dependent on a multitude of factors, such as patient treatment history, stage of disease, genetic factors, as well as inherent tolerability to hypovascular environments—something observed in certain cancer types (recently reviewed in ref. 9). Some mechanisms of resistance thought to be mediated largely by the tumor include cooption of established vessels (10) and preexisting expression by the tumor of multiple alternative proangiogenic pathways (i.e., PDGFs, PIGFs, FGFs; ref. 11), which could compensate immediately for the loss of VEGF signaling. Additional compensatory mechanisms may also be *acquired* by the tumor as a response to elevated tumor hypoxia induced by blockade of VEGF signaling and include the upregulation of alternate proangiogenic mediators, such as bFGF and SDF1 α , which could allow for persistent neovascularization despite continued anti-VEGF therapy (12, 13). It is also evident that therapy-induced hypoxia plays a critical role in facilitating the selection of tumor cells that are able to tolerate, and perhaps even thrive,

in low oxygen environments (refs. 14, 15, recently reviewed in ref. 16).

Although resistance to VEGF pathway-targeted therapy may be mediated in large part by these intrinsic or acquired characteristics of the tumor cells, it is increasingly clear that the mechanisms involving the tumor microenvironment—either directly (in response to drug action) or indirectly (in response to cues from the tumor)—can also be involved in mediating eventual tumor relapse and regrowth. For example, stromal cells such as tumor associated fibroblasts (TAFs) can upregulate PDGF-C in response to VEGF inhibition (17). Pericytes could also play a role by retaining vascular function following endothelial cell (EC) disruption (18), regulating EC proliferation (9, 19), and/or providing a scaffold (along with remaining basement membrane-associated cells) for rapid revascularization after cessation of the therapy (20). Moreover, various types of proangiogenic bone marrow-derived cells (BMDCs) may home to the tumor microenvironment and mediate resistance to VEGF pathway blockade via the production of the aforementioned compensatory proangiogenic factors (3). Examples include circulating cells such as Gr1⁺CD11b⁺ myeloid suppressor-type cells (21) via Bv8 (prokineticin) and G-CSF-dependent mechanisms (22), TIE2-expressing monocytes via upregulation of angiopoietin-2 (23), and tumor-associated macrophages (also via upregulation of Bv8; ref. 24), and there are likely others (25). Taken together, these tumor- and host-mediated mechanisms, either alone or together in concert, may diminish response to antiangiogenic agents despite continued therapy. But what are the phenotypic characteristics of tumors that progress after initial benefit with antiangiogenic therapy?

Implications for tumor invasion and metastasis. The progression of a locally growing primary tumor to the growth of distant metastases involves a number of steps, including a loss of cellular adhesion; augmented motility and invasion capabilities; intravasation into the bloodstream; homing and survival; extravasation and seeding of micrometastases; and finally colonization and growth in a new distant site (26). Because of the integral role of the vasculature in this process, one obvious theoretical advantage of antiangiogenic therapy would be that some of these steps may be compromised, particularly in primary tumors (e.g., via the destruction of the immature vasculature to prevent and/or suppress intravasation), as well as in distant sites (e.g., the prevention of the “angiogenic switch” in avascular metastases). To date, extensive preclinical and clinical studies using VEGF pathway-targeting drugs have indeed been shown to stop or slow the growth of localized primary tumors or established metastatic disease, but it remains largely unknown how effective antiangiogenic therapy is at blocking earlier stages of metastatic disease. Clues that antiangiogenic agents may not sufficiently suppress metastasis in many cases and, even more provocatively, possibly select for more invasive and metastatic tumor phenotypes, have recently emerged. For example, in preclinical tumor models of GBM in which VEGF or HIF1 α was genetically or therapeutically blocked (10, 27, 28), tumors initially shrank, but elevated hypoxia in the tumor microenvironment eventually caused or facilitated recurrent tumor growth in existing and adjacent sites. Moreover, Paez-Ribes and colleagues recently showed that therapy with anti-VEGFR antibodies or various VEGF RTKIs in genetically engineered *RIP1-Tag2* pancreatic islet cell tumors and in orthotopically transplanted GBMs eventually resulted in tumors capable of in-

creased invasion and metastasis in distant organs (such as the liver; ref. 29). Thus, in response to hypoxia induced by anti-VEGF pathway-targeted therapy, tumors may acquire adaptive and/or evasive behavior. Interestingly, tumor-independent (host-mediated) pathways of resistance to angiogenesis inhibition may also facilitate tumor growth and metastasis in certain instances. For example, following short-term (7-day) treatment with various VEGF RTKIs in mice prior to intravenous inoculation of human tumor cells, or immediately after removal of a primary tumor, accelerated metastasis could be observed concomitant with decreased survival (30).

But how can this be explained? Many possible mechanisms could be involved. For example, therapy-induced increases in tumor hypoxia and HIF1 α expression following VEGF-pathway inhibition can lead to (i) increased c-met expression (31, 32) or IL6 expression (33); (ii) activation and/or upregulation of various matrix metalloproteinases (34); (iii) mobilization of BMDCs (35); (iv) instigation of tumor epithelial-to-mesenchymal transition (EMT) (ref. 36); all of which could increase invasive and/or metastatic potential in a “tumor-mediated” manner. Tumor-independent (“host-mediated”) mechanisms could contribute as well, for example, via aforementioned therapy-induced upregulation of various proangiogenic molecules—many of which may increase the invasive and/or metastatic potential of cancer cells. For instance, it is now well documented that increases in VEGF and PlGF, and decreases in sVEGFR-2, can be observed in the plasma of patients receiving VEGF RTKIs (including sorafenib, sunitinib, and many others), such that it can be considered a “class effect” for these agents (see Supplementary Table 1 in ref. 37). Indeed this observation is a major reason why these proteins are currently being evaluated for use as potential surrogate biomarkers for tumor response (38, 39). However, many of these changes could derive, at least in part, from a systemic host-mediated response to treatment rather than from the tumor itself. This possibility was raised in the course of recent experiments from our laboratory that showed that dose-dependent, reversible elevations in VEGF/PlGF (and decreases in sVEGFR-2) could be recapitulated in healthy tumor-free mice treated with VEGF RTKIs and could include many “off-target” molecules such as osteopontin, G-CSF, and SDF1 α (13, 37). Given that many of these circulating proangiogenic cytokines, chemokines, and growth factors have been implicated in promoting angiogenesis and/or metastasis (40–44), it is theoretically possible that they assist in the aforementioned rebound revascularization (20), and/or increased extravasative potential for circulating tumor cells. Such induced systemic host responses to antiangiogenic drugs could facilitate an enhanced “premetastatic niche” precipitated by mechanisms largely independent of the tumor (30, 45). These include: (i) BMDC mobilization, such as the recruitment of circulating VEGFR-1+ bone marrow cells to distant organ sites (46, 47); (ii) pericyte dysfunction, which may in turn make vessels less mature and leaky, and allow for increased extravasative and/or metastatic tumor potential (48); (iii) increased prothrombotic events, which may be caused directly or indirectly by vessel damage as a result of therapy and allow for increased tumor cell “seeding” and growth in distant organs (49); (iv) altered EC adhesion molecule function, a possibility that was raised in a recent study that showed that inhibitors of $\alpha_v\beta_3/\alpha_v\beta_5$ administered continuously at low doses can enhance VEGF-driven angiogenesis and tumor growth (50); and (v) inflammatory pathway activation, which may lead to

alterations (or injury) to the endothelial microenvironment, collectively increasing both intra- and extravascular potential for tumor cells (51). Thus both tumor- and host-mediated responses to antiangiogenic therapy, at least in certain instances, can facilitate proinvasive and metastatic potential after treatment in early-stage micrometastatic disease.

Although eventual enhancement of metastasis in response to an anticancer therapy may, at first glance, seem a counterintuitive concept (irrespective of whether mediated by tumor- or host-related mechanisms), it is important to note that similar findings have been reported for more than 30 years with cytotoxic treatments, including radiation and various chemotherapeutic drugs (52–54). Of course a presumed difference is that chemotherapy and radiation treatments act mainly by direct tumor cytotoxicity, e.g., by nonspecifically targeting proliferating cells, whereas antiangiogenic agents primarily target host processes. Furthermore, cytotoxic (and toxic) chemotherapy and radiation are administered for defined periods, e.g., 3 to 6 months, whereas antiangiogenic agents are (at least theoretically) meant to be administered for longer periods of time, if not indefinitely.

Clinical-Translational Advances

Is there clinical evidence of increased invasion and/or metastasis after VEGF pathway-targeted therapy? Although many host- and tumor-mediated pathways of resistance may explain, at least in part, some of the modest benefits attained in the majority of patients treated with anti-VEGF pathway-targeted agents, it remains unclear whether antiangiogenic therapy will lead to increased invasion and/or metastasis after either prolonged or short-term treatments in the clinic. To date, the literature surrounding this point remains largely anecdotal and limited to case reports or small studies, but there are some clues that suggest relapsed tumors may have an altered and/or increased progression after therapy stops working and/or when therapy is halted altogether. For example, in many instances human GBM patients treated with bevacizumab in combination with chemotherapy experience eventual tumor relapse and/or regrowth accompanied by a high rate of diffuse infiltrative lesions (55–59)—a finding suggestive of an adaptive-evasive response to antiangiogenic therapy leading to increased invasiveness. There are also instances in which discontinuation of anti-VEGF pathway-targeted therapy may support preclinical observations of “rebound revascularization,” something that in turn could influence tumor regrowth and/or metastasis. For example, cases of tumor “flares” have been reported during drug-free break periods (60), after treatment discontinuation in RCC patients receiving either sunitinib or sorafenib (61, 62), or in CRC patients treated with bevacizumab in combination with chemotherapy (63). Furthermore, in addition to primary tumor regrowth after treatment cessation with various VEGF RTKIs, increases in local foci or metastatic spread in distant organs have been noted in certain retrospective analyses (64). Importantly, there are emerging clues that some patients having failed to respond to (or been taken off) VEGF RTKI treatment, may respond again with the same drug after a break period (64), or respond when the drug is switched for another (e.g., sunitinib to sorafenib or *vice versa*) (refs. 65, 66).

Antiangiogenic therapy and micrometastatic disease: implications for adjuvant therapy? To date, one of the difficulties in

uncovering (and predicting) antiangiogenic drug resistance mechanisms is a general disconnect between how such drugs are evaluated in experimental and clinical settings. For example, in most cases, patients in early phase clinical trials receiving antiangiogenic agents (or any other type of anticancer drug and/or therapy for that matter) have late-stage metastatic disease, often in multiple sites, whereas the majority of preclinical work focuses on localized primary tumors (67). Thus, it is essential that future testing of antiangiogenic (and other) therapies address this gap by investigating anticancer agents during various stages of tumor progression, especially when advanced metastatic disease is already established, or, conversely, when only microscopic metastases are present. These considerations are of particular relevance because (i) metastasis is generally the main reason for patient mortality rather than primary tumor growth (68), and (ii) antiangiogenic agents are now being evaluated in earlier stages of disease such as in the adjuvant setting, which may involve neither primary tumors or established metastasis, but rather early-stage occult micrometastatic disease. Indeed, surprisingly few preclinical studies have tested anti-VEGF targeted pathway drugs in early (micro) and late (established) stage metastasis, and even fewer still have directly compared antitumor efficacy in these indications to locally grown primary tumors. In such cases, mixed results have been observed, some of which may help explain modest clinical efficacies. For instance, VEGF RTKIs generally have been shown to slow or stop primary tumor growth in mice, but the effects on established metastatic disease range from efficacious (69), to only a marginal or negligible benefit on the overall survival of mice (71). Moreover, in micrometastatic and/or early stage disease, the aforementioned studies by our and the Paez-Ribes and colleagues' groups show that VEGF pathway-targeted therapy can, in certain instances, result in increased tumor invasiveness and metastasis. Critically, such results contrasted in both studies with the potent tumor growth inhibitory effects the same drugs and treatment schedules had on locally grown primary tumors (29, 30). It is likely that various experimental conditions—such as the animal model, tumors, drugs, doses, treatment duration, or combinations with chemotherapy—may explain some of these differences in experimental outcomes; however, it is possible that differential efficacies with antiangiogenic therapy may be observed between micro- and macrometastatic disease. Some studies with genetically engineered mouse models of intestinal adenomas (APC^{min} mice) show that tumor growth can be slowed and survival prolonged after treatment with various inhibitors of the VEGF pathway (72–74). Similarly, transgenic mouse models of NSCLC, generated by mutations in *Kras* showed improved survival in mice treated with sunitinib starting 4 weeks after metastatic tumor growth was induced by conditional *Lkb1* deletion. Yet, outcome in this latter instance was not further improved if treatment started 2 weeks earlier (75, 76), raising the question whether observed benefits after treatment were because of effects against established metastasis rather than microscopic disease.

Such distinctions could be important for interpretation of both preclinical and clinical trials involving antiangiogenic agents in the adjuvant setting (77). In limited preclinical models in which primary tumors are removed and antiangiogenic drug treatment is initiated, metastatic growth could be inhibited (69, 78) or accelerated (30), depending on the tumor models and drugs used, and when treatments are initiated. It is clear that more studies should be conducted preclinically to test anti-VEGF

pathway-targeted therapy in an authentic adjuvant setting, i.e., very shortly or immediately after surgical resection of a primary tumor when only microscopic minimum residual disease is present—something that might be determined by various imaging techniques and/or other measures (79). Ironically, it might be that this question will be addressed and answered first in the clinical setting. Currently there are more than 40+ adjuvant clinical trials underway involving multiple VEGF pathway inhibitors, such as sorafenib and sunitinib (80), as well as bevacizumab (typically in combination with chemotherapy), in numerous cancer types, including breast, renal, prostate, head and neck cancers, NSCLC, ovarian, and others.¹ With respect to bevacizumab, one such trial has been completed as of 2009. In this phase III study, postoperative colorectal patients with stage II–III disease were treated with the anti-VEGF antibody plus chemotherapy for 1 year and 6 months, respectively. The results of this trial² showed no benefit in PFS when assessed 3 years after therapy initiation (81). Interestingly, a clear benefit in favor of bevacizumab at 1 year (when therapy was completed) was observed, but this benefit gradually disappeared over time. The

basis for this phenomenon is unknown and clearly highlights the urgent need for undertaking preclinical studies in appropriate models to examine the mechanisms by which antiangiogenic treatments such as VEGF pathway-targeted drugs lose their activity and/or alter tumor progression and metastasis over time.

Conclusion

Although anti-VEGF pathway-targeted therapies represent an effective treatment of cancer in certain settings, substantial benefits remain unrealized for the vast majority of patients in terms of overall survival. Preclinical testing has uncovered mechanisms of resistance that may, in certain instances, be differentiated between host- and tumor-mediated processes, some of which could explain limitations seen with the use of antiangiogenic drugs in the clinical setting. Further understanding of these mechanisms, as well as consideration of the potential differential efficacies of treatments at different stages of tumor progression, will be key to devising rational strategies in overcoming the challenges facing further development of antiangiogenic therapies.

Disclosure of Potential Conflicts of Interest

R.S. Kerbel, employment, commercial research grant, GlaxoSmithKline; honoraria, Roche, Genentech; consultant, Cerulean, MolMed, Oxigene.

¹ <http://clinicaltrials.gov>. Search bevacizumab or sunitinib or sorafenib and adjuvant.

² <http://clinicaltrials.gov>, NSABP-C-08; <http://clinicaltrials.gov>, NCT00096278.

References

- Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov* 2007;6:273–86.
- Heath VL, Bicknell R. Anticancer strategies involving the vasculature. *Nat Rev Clin Oncol* 2009;6:395–404.
- Kerbel RS. Tumor angiogenesis. *N Engl J Med* 2008;358:2039–49.
- Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349:427–34.
- Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666–76.
- Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). *J Clin Oncol* 2009;27:CRA8003.
- Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? *Science* 2006;312:1171–5.
- Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls. *Cancer Metastasis Rev* 1996;15:231–6.
- Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer* 2008;8:592–603.
- Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. *Neoplasia* 2000;2:306–14.
- Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Res* 1997;57:963–9.
- Casanovas O, Hicklin D, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late stage pancreatic islet tumors. *Cancer Cell* 2005;8:299–309.
- Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 2007;11:83–95.
- Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. *Crit Rev Oncol Hematol* 2006;59:15–26.
- Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to anti-angiogenic therapy. *Science* 2002;295:1526–8.
- Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to antiangiogenic therapies. *Drug Resist Updat* 2009;12:74–80.
- Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. *Cancer Cell* 2009;15:21–34.
- Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. *J Clin Invest* 2003;111:1287–95.
- Hirschi KK, D'Amore PA. Control of angiogenesis by the pericyte: molecular mechanisms and significance. *EXS* 1997;79:419–28.
- Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. *J Clin Invest* 2006;116:2610–21.
- Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. *Nat Biotechnol* 2007;25:911–20.
- Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. *Proc Natl Acad Sci U S A* 2009;106:6742–7.
- Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. *Cancer Res* 2007;67:8429–32.
- Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer* 2009;9:239–52.
- Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. *Nat Rev Cancer* 2006;6:835–45.
- Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer* 2009;9:274–84.
- Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth *in vivo* by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. *Cancer Res* 2001;61:6624–8.
- Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. *Cancer Cell* 2003;4:133–46.
- Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell* 2009;15:220–31.
- Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. *Cancer Cell* 2009;15:232–9.
- Pennacchiotti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia

- promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell* 2003;3:347–61.
32. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? *Nat Med* 2003;9:822–3.
 33. Saidi A, Hagedorn M, Allain N, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. *Int J Cancer* 2009;125:1054–64.
 34. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. *Curr Mol Med* 2003;3:659–71.
 35. Du R, Lu KV, Petritsch C, et al. HIF1 α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* 2008;13:206–20.
 36. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis *in vivo* via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J Clin Invest* 2007;117:3810–20.
 37. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. *Proc Natl Acad Sci U S A* 2007;104:17069–74.
 38. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. *J Transl Med* 2007;5:32.
 39. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. *Nat Rev Cancer* 2006;6:626–35.
 40. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. *Cell* 2008;133:994–1005.
 41. Ben Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. *Clin Exp Metastasis* 2008;25:345–56.
 42. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. *Cancer Metastasis Rev* 2008;27:103–18.
 43. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. *Biochem Biophys Res Commun* 2002;297:1058–61.
 44. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. *Cancer Res* 2000;60:6757–62.
 45. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. *Cancer Cell* 2009;15:167–70.
 46. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005;438:820–7.
 47. Steeg PS. Cancer biology: emissaries set up new sites. *Nature* 2005;438:750–1.
 48. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. *J Clin Invest* 2006;116:642–51.
 49. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. *Best Pract Res Clin Haematol* 2009;22:115–28.
 50. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. *Nat Med* 2009;15:392–400.
 51. Bidard FC, Pierga JY, Vincent-Salomon A, Poupon MF. A “class action” against the microenvironment: do cancer cells cooperate in metastasis? *Cancer Metastasis Rev* 2008;27:5–10.
 52. van Putten LM, Kram LK, van Dierendonck HH, Smink T, Fuzy M. Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. *Int J Cancer* 1975;15:588–95.
 53. Vollmer TL, Conley FK. Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells. *Cancer Res* 1984;44:3902–6.
 54. de Ruiter J, Cramer SJ, Lelieveld P, van Putten LM. Comparison of metastatic disease after local tumour treatment with radiotherapy or surgery in various tumour models. *Eur J Cancer Clin Oncol* 1982;18:281–9.
 55. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. *J Neurosurg* 2008;110:173–80.
 56. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology* 2008;70:779–87.
 57. Fischer I, Cunliffe CH, Bollo RJ, et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. *Neuro-oncol* 2008;10:700–8.
 58. Ellis LM, Reardon DA. Cancer: The nuances of therapy. *Nature* 2009;458:290–2.
 59. Mathews MS, Linskey ME, Hasso AN, Fruehauf JP. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. *Surg Neurol* 2008;70:649–52.
 60. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2008;26:1810–6.
 61. Wolter P, Beuselink B, Pans S, Schoffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. *Acta Oncol* 2009;48:621–4.
 62. Desar IM, Mulder SF, Stillebroer AB, et al. The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. *Acta Oncol* 2009;1–4, Epub 2009 May 19.
 63. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. *Ann Oncol* 2008;19:1659–61.
 64. Johannsen M, Florcken A, Bex A, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. *Eur Urol* 2008; Epub 2008 Oct 18.
 65. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. *J Urol* 2009;182:29–34.
 66. Dudek AZ, Zolnierok J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. *Cancer* 2009;115:61–7.
 67. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived – but they can be improved. *Cancer Biol Ther* 2003;2:S134–9.
 68. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. *Nat Clin Pract Oncol* 2008;5:206–19.
 69. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Non-clinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. *Clin Cancer Res* 2008;14:7272–83.
 70. Schomber T, Zumsteg A, Strittmatter K, et al. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. *Mol Cancer Ther* 2009;8:55–63.
 71. Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. *Mol Cancer Ther* 2008;7:2272–9.
 72. Korsisaari N, Kasman IM, Forrest WF, et al. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc^{+/min} mice. *Proc Natl Acad Sci U S A* 2007;104:10625–30.
 73. Alferez D, Wilkinson RW, Watkins J, et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min⁺) mice. *Mol Cancer Ther* 2008;7:590–8.
 74. Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. *Carcinogenesis* 2006;27:2133–9.
 75. Gandhi L, McNamara KL, Li D, et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. *Cancer Prev Res* 2009;2:330–7.
 76. Grandis JR, Argiris A. Targeting angiogenesis from premalignancy to metastases. *Cancer Prev Res* 2009;2:291–4.
 77. Schneider BP, Sledge GW, Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? *Breast Cancer Res* 2009;11:303.
 78. Mizobe T, Ogata Y, Murakami H, et al. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. *Oncol Rep* 2008;20:517–23.
 79. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. *Nat Rev Clin Oncol* 2009;6:339–51.
 80. Kapoor A, Gharajeh A, Sheikh A, Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. *Curr Oncol* 2009;16 Suppl 1:S60–S66.
 81. Wolmark N, Yothers G, O’Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. *J Clin Oncol* 27:18S.

Clinical Cancer Research

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

John M. L. Ebos, Christina R. Lee and Robert S. Kerbel

Clin Cancer Res 2009;15:5020-5025. Published OnlineFirst August 11, 2009.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-09-0095](https://doi.org/10.1158/1078-0432.CCR-09-0095)

Cited articles This article cites 78 articles, 18 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/15/16/5020.full#ref-list-1>

Citing articles This article has been cited by 39 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/15/16/5020.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/15/16/5020>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.